LY2875358, ERLOTINIB clinical trials

I4C-MC-JTBB: A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic NSLC Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib

This study looks at a new drug, LY2875358, combined with an existing lung cancer treatment, erlotinib, for people with a specific type of advanced non-small cell lung cancer. It compares this combination to using erlotinib alone to see if it helps patients live longer without their cancer growing.